Serotonin Signaling

Overview

Serotonin — chemically, 5-hydroxytryptamine or 5-HT — is one of the most anatomically distributed signaling molecules in the body. Despite its association with mood, only about 2% of the body's serotonin lives in the brain. The remainder is produced by enterochromaffin cells of the gut, where it regulates peristalsis and secretion, and by platelets, which release it to constrict injured vessels. CNS serotonin originates almost exclusively in the raphe nuclei of the brainstem, whose neurons project diffusely to nearly every region of the forebrain.

Few signaling systems rival serotonin for receptor diversity: at least fourteen distinct 5-HT receptor subtypes have been cloned, spread across seven families. All but one are G-protein coupled; the sole ionotropic exception, 5-HT3, is a ligand-gated cation channel responsible for the nausea signal that antiemetic drugs block. Peptides including Selank, Semax, and DSIP are studied for their effects on serotonergic tone, while gut serotonin is modulated by processes described in the gut-brain axis.

How It Works

Synthesis. Tryptophan hydroxylase (TPH1 peripherally, TPH2 in the CNS) converts tryptophan to 5-hydroxytryptophan using tetrahydrobiopterin and oxygen. Aromatic amino acid decarboxylase then removes the carboxyl group to yield serotonin. Because TPH is not normally saturated with substrate, dietary tryptophan availability — competing with other large neutral amino acids for brain transport — measurably influences brain serotonin synthesis.

Vesicular storage and release. VMAT2 packages serotonin into synaptic vesicles. Raphe neurons fire in slow, pacemaker-like patterns; action potentials trigger calcium-dependent vesicular release through the standard mechanism covered in neurotransmission.

Receptors. The 5-HT1 family (Gi-coupled, inhibitory) includes the 5-HT1A autoreceptor on raphe soma and the 5-HT1B terminal autoreceptor. The 5-HT2 family (Gq-coupled, excitatory via PLC/IP3/DAG) includes 5-HT2A, the principal target of psychedelics. 5-HT3 is an ionotropic cation channel. 5-HT4, 5-HT6, and 5-HT7 are Gs-coupled and raise cAMP.

Termination. The serotonin transporter (SERT) pumps released 5-HT back into the presynaptic terminal for recycling or degradation by monoamine oxidase A. SERT is the molecular target of SSRIs.

Functional Roles

Mood and affect. The monoamine hypothesis of depression centers on deficient serotonergic signaling, though the biology is more nuanced than simple neurotransmitter depletion. SSRIs raise synaptic serotonin within hours but produce clinical benefit only over weeks, implying downstream plasticity changes — BDNF induction, neurogenesis in the hippocampal dentate, and 5-HT1A autoreceptor desensitization — as the actual therapeutic substrate.

Sleep and circadian function. Serotonin is the biosynthetic precursor to melatonin in the pineal gland and modulates sleep onset through raphe projections to the suprachiasmatic nucleus. DSIP is studied in connection with delta-wave sleep that partly tracks serotonergic tone.

Appetite and feeding. 5-HT2C receptors in the hypothalamic arcuate nucleus suppress food intake. Lorcaserin (withdrawn) and the long-standing knowledge that SSRIs can blunt appetite stem from this pathway.

Gut motility. Enterochromaffin-cell serotonin activates 5-HT3 on vagal afferents and 5-HT4 on enteric neurons to coordinate the peristaltic reflex. 5-HT3 antagonists such as ondansetron suppress vomiting and chemotherapy-induced nausea.

Vascular. Platelet serotonin constricts injured vessels, aiding primary hemostasis. In the pulmonary circulation, sustained serotonin excess contributes to pulmonary hypertension — a historical hazard of certain appetite suppressants.

Psychedelics and 5-HT2A

Classical psychedelics (LSD, psilocin, DMT, mescaline) are 5-HT2A partial agonists. Activation of 5-HT2A on cortical layer 5 pyramidal neurons triggers asynchronous glutamate release, promotes BDNF-dependent dendritic spine growth, and acutely fragments the default-mode network. Ongoing trials test psilocybin for treatment-resistant depression, where it appears to produce durable benefit after just one or two dosed sessions.

Serotonin Syndrome

Excessive serotonergic activity — typically from drug combinations such as an MAOI plus an SSRI — produces clonus, hyperthermia, autonomic instability, and altered mental status. The syndrome reflects overactivation of postsynaptic 5-HT1A and 5-HT2A receptors and can be life-threatening if unrecognized.

Peptide Modulators

Selank is a synthetic analogue of tuftsin studied for its anxiolytic effects that appear to involve enkephalinase inhibition and indirect serotonergic modulation. Semax influences BDNF, brain-derived growth factors, and monoaminergic tone. Melanotan II interacts with melanocortin receptors that in turn shape serotonin and dopamine release in hypothalamic circuits.